share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC ·  Sep 4 04:32
Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 09/03/2024, as per the latest filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for services, are valued at an aggregate market price of $71,717.45. This planned transaction follows a series of sales over the past three months, where Borgeson sold a total of 68,682 Class A shares, amounting to gross proceeds of $545,960.29.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 09/03/2024, as per the latest filing. These shares, originally acquired on 09/01/2016 as founder's shares in compensation for services, are valued at an aggregate market price of $71,717.45. This planned transaction follows a series of sales over the past three months, where Borgeson sold a total of 68,682 Class A shares, amounting to gross proceeds of $545,960.29.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.